See Bull Run's company pages for Cipla and Lupin. Investors can also compare Lupin against a larger specialty-pharma platform in Bull Run's Sun Pharma vs Lupin analysis.

Q1 FY27 scorecard: Lupin produced more profit on a similar market cap

Cipla's Q1 weakness was primarily a North America problem

Cipla's North America business generated approximately US$162 million in Q1 FY27.

The comparable Q1 FY26 figure was about US$226 million.

That represents a decline of roughly 28%.

The biggest reason was the normalization of high-value products that had supported earlier quarters.

Lenalidomide economics declined after a strong prior period, while lanreotide supply constraints also affected the business.

This created an unusually difficult comparison.

Lupin's United States business went the other way

US sales increased 42.9% from approximately ₹2,404 crore in Q1 FY26.

The United States represented 42% of Lupin's global sales.

That means the US is now Lupin's single largest geographic market.

Why is Lupin's US business growing?

Lupin has spent years moving toward products with higher barriers to competition.

The strategy includes:

• complex generics;
• respiratory products;
• injectables;
• long-acting injectables;
• biosimilars;
• limited-competition oral products;
• specialty medicines.

These categories can produce much better economics than a conventional generic tablet that has ten or fifteen competitors.

Lupin now has enormous prescription scale in the US

The company was the third-largest pharmaceutical player in the US generic and total market by prescriptions during the June 2026 quarter according to company-cited IQVIA data.

It marketed 149 generic products.

Lupin was the market leader in 56 of its marketed generics and among the top three in 112.

It received six ANDA approvals and launched three products in Q1.

The company had received 350 cumulative ANDA approvals by June 30, 2026.

First-to-file opportunities remain valuable—but temporary

Lupin reported 50 first-to-file filings, including 21 exclusive first-to-file opportunities.

These can provide periods of reduced competition and unusually attractive pricing.

But exclusivity eventually ends.

When more competitors enter, price and margin can decline sharply.

The investment case therefore depends on Lupin continuously replacing maturing opportunities with new complex launches.

Cipla is also moving into differentiated US products

Cipla should not be viewed as a simple commodity-generics company.

It has developed strong capabilities in inhalation and respiratory products.

During Q1 FY27, Cipla launched the first AB-rated generic Ventolin inhaler in the US and began initial shipments.

Its generic Proventil product already ranked first in the US albuterol metered-dose inhaler market by company-cited IQVIA data.

Cipla said it had supplied more than 50 million inhaler units cumulatively to the US market.

Respiratory is Cipla's deepest competitive moat

Cipla has spent decades developing inhalation technology across India and regulated markets.

Respiratory products involve:

• device engineering;
• formulation science;
• dose consistency;
• regulatory equivalence;
• manufacturing precision;
• patient-device usability.

These barriers can reduce competition compared with standard tablets.

If Cipla's new US respiratory launches scale successfully, the current North America weakness can reverse.

Cipla's current US revenue is therefore not necessarily normalized

Cipla entered FY27 expecting margins above the Q1 level over the full year.

That means part of the comparison with Lupin captures opposite points in their product cycles.

Lupin is currently enjoying strong differentiated-product momentum.

Cipla is currently waiting for new respiratory and peptide-related products to replace earlier high-profit products.

India completely reverses the geographic comparison

Cipla's Indian business was about 45% larger.

India represented 48% of Cipla's revenue versus 29% of Lupin sales.

Cipla is therefore substantially less dependent on the US product cycle at the consolidated revenue level.

Cipla's India business grew 12%

The company delivered its highest-ever first-quarter One-India revenue.

Its branded prescription portfolio grew around 15.4% in market terms according to company-cited IQVIA data.

Key chronic therapies remained strong.

Cipla reported market growth of approximately:

• 13% in respiratory;
• 10% in urology;
• 26% in anti-diabetes;
• 14% in cardiac;
• 11% in dermatology.

Chronic medicines now dominate Cipla's prescription franchise

Cipla's chronic mix increased to approximately 60.4%.

That is strategically important because chronic medicines create repeat demand.

A hypertension, diabetes or respiratory patient can remain on treatment for years.

This generally creates more predictable revenue than short-course anti-infectives.

Foracort remains an exceptional Indian pharmaceutical asset

Cipla's Foracort franchise remains one of India's largest pharmaceutical brands and the country's biggest respiratory brand according to company disclosures.

Cipla also has numerous other brands with annualised revenue above ₹100 crore.

Brand scale creates barriers through:

• physician familiarity;
• distribution;
• patient trust;
• repeat prescriptions;
• therapy leadership.

Lupin's India franchise is smaller but improving

Lupin's India sales increased 13.9% to approximately ₹2,380 crore.

India Region formulation growth was approximately 15.1%.

The company launched seven brands during Q1.

Lupin is currently the eighth-largest company in the Indian pharmaceutical market according to company-cited IQVIA data.

Lupin's chronic portfolio is becoming more valuable

Lupin has significant franchises across:

• cardiology;
• diabetes;
• respiratory;
• CNS;
• gastroenterology;
• women's health;
• urology.

Its increasing chronic mix helps reduce dependence on acute anti-infective demand and improves prescription durability.

Cipla has the stronger domestic respiratory franchise

Respiratory is one of Cipla's defining capabilities.

It ranks first in India's respiratory market according to company-cited market data.

The same scientific and commercial capability also supports Cipla's US inhalation strategy.

This creates a rare cross-market technology advantage.

Lupin has the stronger Q1 geographic breadth of growth

Lupin's strong quarter was not limited to the United States.

Other Developed Markets sales increased 48.3% to approximately ₹1,149 crore.

Emerging Markets increased 51.7% to approximately ₹990 crore.

API sales increased 8.5%.

All four major formulation geographies therefore grew double digits.

Cipla's international portfolio is more mixed

Cipla's One Africa and Emerging Markets & Europe businesses continued contributing important revenue, but their scale was not enough to offset the North America decline.

The company remains strategically diversified across India, North America, Africa and other emerging markets.

That diversification becomes valuable when individual US products decline.

R&D intensity currently favours Lupin

Lupin invested approximately ₹608 crore in R&D during Q1, equal to 7.4% of sales.

Cipla invested approximately ₹486 crore, equal to 6.8% of revenue.

Lupin therefore spent more both in absolute rupees and as a percentage of revenue.

The spending supports differentiated products that can potentially replace today's high-profit launches.

Cipla's pipeline is concentrated around high-value opportunities

Cipla's US pipeline includes respiratory, peptide and other differentiated opportunities.

The company had more than 100 approved ANDAs and NDAs across relevant US entities according to its Q1 presentation.

The critical issue is timing.

Approval can be economically valuable only if launch occurs before the competitive window becomes crowded.

Balance sheets are strong for both companies

Cipla has the larger cash cushion.

Lupin's move into net cash is nevertheless significant because its historical leverage was higher.

A stronger balance sheet gives Lupin greater flexibility to invest in complex generics, specialty assets and biosimilars.

Capital efficiency currently strongly favours Lupin

Lupin's current ROCE is approximately double Cipla's.

This reflects its sharply improved profitability.

But pharmaceutical return ratios can move rapidly when temporary exclusivity products enter or leave the profit base.

Investors should therefore watch whether Lupin can sustain high returns after product normalisation.

Cipla's five-year cash record is stronger

Bull Run's historical field shows approximately ₹13,262 crore of cumulative five-year free cash flow for Cipla versus around ₹9,388 crore for Lupin.

This matters because one quarter does not erase several years of cash-generation history.

Cipla's large net cash position was built through this cumulative cash generation.

Valuation is the biggest argument for Lupin

The companies have almost identical market capitalisations.

But Lupin's current trailing earnings are much larger, resulting in a substantially lower P/E.

That makes Lupin's valuation difficult to ignore.

Why does Cipla still command the higher P/E?

The market is effectively assuming that Cipla's current earnings are depressed.

Investors expect some combination of:

• US respiratory launch ramp-up;
• normalisation of temporary expenses;
• continued India growth;
• new differentiated products;
• higher future EBITDA margin.

Lupin's earnings, by contrast, may contain more contribution from products enjoying limited competition today.

The market therefore applies a larger normalization discount to Lupin.

The market-cap comparison is unusually useful

Cipla is valued at approximately ₹1.16 lakh crore.

Lupin is valued at approximately ₹1.14 lakh crore.

An investor choosing between them is therefore allocating almost the same amount of market value to two very different earnings profiles.

Today:

• Lupin earns more;
• Lupin grows faster;
• Lupin has higher ROCE;
• Cipla has more net cash;
• Cipla has a larger India business;
• Cipla's current US earnings appear more depressed.

Share-price momentum also favours Lupin

Bull Run's September snapshot shows Lupin up approximately 13.4% over one year.

Cipla is down approximately 10.3%.

This suggests investors have already rewarded part of Lupin's earnings recovery.

But the P/E remains lower because profit growth has outpaced the share-price rerating.

What must Cipla prove?

• North America revenue must stabilise and recover.
• gVentolin and other differentiated launches need commercial scale.
• Q1's 16.7% EBITDA margin needs to improve.
• India should sustain double-digit growth.
• Respiratory and chronic market leadership must remain strong.
• R&D spending must produce new high-value launches.
• Net cash should be allocated without lowering returns.

What must Lupin prove?

• US growth must survive product exclusivity normalisation.
• Complex generics need to become an increasingly large share of US profit.
• 31%-plus Q1 EBITDA margin should remain structurally high.
• India needs continued mid-teens growth.
• Biosimilar launches should scale profitably.
• Regulatory compliance must remain strong.
• ROCE should remain high after the current US product cycle matures.

What could make Cipla outperform Lupin?

An earnings recovery from a depressed base.

If Cipla's North America business moves from US$162 million back toward a materially higher quarterly run rate while India continues growing double digits, EBITDA can recover much faster than revenue.

The stock does not need 30% revenue growth to create strong earnings growth if margin normalises.

What could make Lupin outperform Cipla?

Sustained complex-generics execution.

If Lupin continues introducing differentiated inhalation, injectable, biosimilar and first-to-file products, its current 20.6x P/E can remain attractive even if Q1's 33% sales growth moderates.

Which has the stronger US business today?

Lupin.

Q1 US sales were approximately US$366 million versus Cipla North America at US$162 million, and Lupin's business was growing rapidly.

Which has the stronger India business?

Cipla.

One-India revenue reached ₹3,452 crore compared with Lupin India sales of approximately ₹2,380 crore.

Which has the stronger current margin?

Lupin.

Its disclosed Q1 EBITDA margin was 31.4% versus Cipla at 16.7%.

But Cipla's quarter appears substantially below its normalized profitability potential.

Which has the stronger balance sheet?

Cipla on absolute net cash.

It reported approximately ₹9,494 crore net cash versus Lupin around ₹2,831 crore.

Which has the stronger valuation?

Lupin.

Its trailing P/E is approximately 20.6x compared with Cipla around 34.5x.

Which is better: Cipla or Lupin?

Lupin currently has the stronger valuation-adjusted operating profile. It generated more Q1 revenue, more than twice Cipla's EBITDA, almost 80% more PAT, substantially higher ROCE and trades at a much lower P/E despite having almost exactly the same market capitalisation.

Cipla currently has the stronger India and earnings-recovery profile. Its record ₹3,452 crore One-India business, respiratory leadership and ₹9,494 crore net cash provide significant resilience while new US launches attempt to rebuild North America earnings.

The central distinction is the earnings cycle.

Lupin is currently operating near a strong point in its US differentiated-product cycle.

Cipla is currently operating near a weak point in its North America cycle.

At September 2026 valuations, Lupin has the better current growth-and-value combination. Cipla becomes more attractive if US respiratory launches successfully restore revenue and EBITDA margin, because current Q1 profitability leaves substantial room for recovery.

Frequently asked questions